EMBO/SourceData huggingface dataset:
Figure legend: "A The loss-of-function mutants akt1-1 and akt1-2 are salt-sensitive. Six-d-old seedlings of Col-0 (WT) and akt1 mutants were treated with or without 100 mM NaCl for 7 d. B Analysis for primary root length, related to Fig 5A. Data was shown in a box and whiskers (min to max) form (n ≥ 10). Statistical analysis was done by two-way ANOVA with Holm-Sidak's multiple comparisons test (P ≤ 0.05). C"
NCBI gene IDs:
"akt1: "
Figure legend: "C, D Analysis of the average values of the net Na+ (C) and K+ (D) fluxes of Col-0 and akt1 mutants with or without 100 mM NaCl treatment for 24 h. Error bars represent SD (n ≥ 4)."
NCBI gene IDs:
"akt1: "
Figure legend: "K Time- and voltage-dependent AKT1-mediated K+ current recordings from oocytes. Whole-cell K+ currents were recorded in oocytes that were co-injected with indicated mixture of cRNAs for AKT1, SCaBP8 and SOS2 (SOS2WT or SOS2K57G), in the presence of CIPK23 and CBL1. 30% SOS2 means that the cRNA injection amount of SOS2 was 30% of SCaBP8. The oocytes were treated with or without 50 μM PA for 1.5 h."
NCBI gene IDs:
"AKT1: 
SCaBP8: 
CBL1: 827481
CIPK23: 839907
SOS2: 833502"
Figure legend: "D SOS2K40N and SOS2T168D∆FISL attenuate the SCaBP8-mediated inhibition of AKT1 in oocytes. The recorded oocytes were co-injected with indicated mixture of cRNAs for AKT1, SCaBP8 and SOS2 (SOS2WT, SOS2T168D∆FISL or SOS2K40N) in the presence of CIPK23 and CBL1."
NCBI gene IDs:
"AKT1: 
SCaBP8: 
SOS2: 833502"
Figure legend: "E I-V relationship of AKT1 steady-state currents in oocytes. Error bars represent SD (n ≥ 7)."
NCBI gene IDs:
"AKT1: "
Figure legend: "(B) Dot-plot showing the fold change (log2) in number of reads between vehicle and AZD8186-treated conditions vs the p-value of the difference between the two treatment conditions for each shRNA. 9 out of 18 shRNAs targeting EGFR showed a p-value &lt;0.2 and are highlighted in the plot. The plot was generated considering the results from biological triplicate of the experiment."
NCBI gene IDs:
"EGFR: 1956"
Figure legend: "(C MDA-MB-468 were infected with the indicated shRNAs targeting EGFR and selected by puromycin. EGFR mRNA was then measured by RT-qPCR (C) Average ± SD of triplicates and representative of three independent experiments."
NCBI gene IDs:
"EGFR: 1956"
Figure legend: "D) MDA-MB-468 were infected with the indicated shRNAs targeting EGFR and selected by puromycin. cell viability was measured after 4 days of treatment with serial dilutions of AZD8186 (D). Average ± SD of triplicates and representative of three independent experiments."
NCBI gene IDs:
"EGFR: 1956"
Figure legend: "(G) Viability of six PTEN-null VS five PTEN-WT TNBC cell lines - not carrying other known mutations in PIK3CA, PIK3CB or PIK3R1 genes - treated with PI3Kβi (AZD8186 90 nM), EGFRi (gefitinib 3 μM) alone or in combination for 6 days. Mean of 3 independent experiments ± SD. Statistical significance of two-tailed unpaired student t-test in PTEN-null PI3Kbi versus PI3Kbi+EGFRi **P=0.0059, PTEN-null EGFRi versus PI3Kbi+EGFRi **P=0.0047, PTEN-null PI3Kbi+EGFRi versus PTEN-WT PI3Kbi+EGFRi *P=0.0459, PTEN-WT PI3Kbi versus PI3Kbi+EGFRi *P=0.0108, PTEN-WT EGFRi versus PI3Kbi+EGFRi n.s. P=0.1926. PTEN-null cell lines used in the experiments were: MDA-MB-468, HCC70, HCC1937, HCC38, HCC1395 and BT-549; PTEN-WT cell lines were: MDA-MB-157, MDA-MB-231, HCC1187, HCC1428 and HCC1806."
NCBI gene IDs:
"PIK3CA: 5290
PIK3CB: 5291
PIK3R1: 5295
PTEN: 5728"
Figure legend: "(H) Synergy score for combinations of serial dilutions of PI3Kβi (AZD8186) plus EGFRi (gefitinib) tested on six PTEN-null and five PTEN-WT TNBC cell lines for 6 days in three independent experiments. The score was obtained analysing the viability data through the software Chalice Analyser. Mean of the synergy scores ± SD. Statistical significance of Mann Whitney two-tailed test *P=0.0303."
NCBI gene IDs:
"PTEN: 5728"
Figure legend: "(I) Patient samples from METABRIC dataset classified as TNBCs were assigned to the groups \"PTEN-low\" when falling in the lower quartile for PTEN expression, \"PTEN-mut\" when harbouring a non-synonymous mutation on PTEN gene, \"PTEN-WT\" in all other cases. Comparison of the expression of EGFR between the PTEN low or mut and the PTEN-WT groups. Data presented in a box and whisker plot with the central band indicating the median, the upper and lower extremes of the box or hinge being the third and first quartiles respectively and the whiskers extending to the most extreme data values Mean ± SD. P value calculated by unpaired t-test."
NCBI gene IDs:
"EGFR: 1956
PTEN: 5728"
Figure legend: "(E) A cell line derived from a mammary tumor spontaneously developed in a Wap-cre:Ptenfl/fl:Tp53fl/fl mouse was cloned and injected in the mammary fat pad of syngeneic C57BL6/J recipient mice. Tumours grew in 12 out of 35 transplanted mice and only these tumours were selected for the treatments described in the figure. When tumours reached an average volume of 100mm3, they were treated with vehicle or a combination of AZD8186 (150mg/kg, og once/day) and erlotinib (50mg/kg IP once/day). Tumours were then measured during the treatment (6 mice per group, mean±SEM). Statistical significance of two-way ANOVA statistical test ****P&lt;0.0001."
NCBI gene IDs:
"cre: 2777477
Pten: 5728
Tp53: 7157
Wap: 22373"
Figure legend: "(A Results of CRISPR-Cas9 screening in combination with AZD8186 100nM (A) The dot-plots show for each gene knocked-out by sgRNAs the fold change (log2) between treated conditions (AZD8186 and vehicle in the fluorescence signal (anti-phosphoS6 immunofluorescence) versus the p-value of the difference calculated by two sided t-test. The plots represent means of biological triplicates. Genes for which it was calculated a p&lt;0.0001 and Log2 (fold change)&gt;0.25 are reported and highlighted in green; genes having a 0.0001 0.25 are reported and shown in red. Gefitinib combined with AZD8186 represents the positive control of the experiment (A). &lt;0.05&gt;"
NCBI gene IDs:
"Cas9: 2777477"
Figure legend: "B) Results of CRISPR-Cas9 screening in combination with GDC0941 400nM (B). The dot-plots show for each gene knocked-out by sgRNAs the fold change (log2) between treated conditions GDC0941, and vehicle in the fluorescence signal (anti-phosphoS6 immunofluorescence) versus the p-value of the difference calculated by two sided t-test. The plots represent means of biological triplicates. Genes for which it was calculated a p&lt;0.0001 and Log2 (fold change)&gt;0.25 are reported and highlighted in green; genes having a 0.0001 0.25 are reported and shown in red. &lt;0.05&gt;"
NCBI gene IDs:
"Cas9: 2777477"
Figure legend: "(C) Box &amp; Whisker plot showing the fold change in fluorescence signal between vehicle and GDC0941-treated conditions for MDA-MB-468 cells transduced with non-target Control, GNB2 or GNG5 sgRNAs (N=2 or 3). Data presented in a box and whisker plot with the central band indicating the median, the upper and lower extremes of the box or hinge being the third and first quartiles respectively and the whiskers extending to the most extreme data values within 1.5 times the inter-quartile range. Statistical significance of unpaired t-test ****P&lt;0.0001."
NCBI gene IDs:
"GNB2: 2783
GNG5: 2787"
Figure legend: "(D) Biochemical analysis of GNB2 KO cells. Cell lysates of MDA-MB-468 parental cells and three MDA-MB-468 GNB2 KO clones were probed with the indicated antibodies. Quantification of the bands was performed by ImageLite software."
NCBI gene IDs:
"GNB2: 2783"
Figure legend: "(A) MDA-MB-468 parental cells and three MDA-MB-468 GNB2 KO clones were treated with vehicle, GDC0941 1 μM, gefitinib 3 μM or lapatinib 1 μM for 24 hours. The cell lysates were probed with the indicated antibodies."
NCBI gene IDs:
"GNB2: 2783"
Figure legend: "(B-D) Viability assays of MDA-MB-468 parental cells and three MDA-MB-468 GNB2 KO clones treated with serial dilutions of the indicated drugs for six days. Mean ± SD of triplicates and representative of two or three independent experiments."
NCBI gene IDs:
"GNB2: 2783"
Figure legend: "(E) Patient samples from METABRIC dataset classified as TNBCs (N=299) were assigned to the groups \"PTEN-low\" when falling in the lower quartile for PTEN expression, \"PTEN-mut\" when harbouring a non-synonymous mutation on PTEN gene, \"PTEN-WT\" in all other cases. Comparison of the expression of GNB2 between the PTEN low or mut and the PTEN-WT groups. Box &amp; Whisker plot (Median/IQR/1.5*IQR Whiskers). P value calculated by unpaired t-test."
NCBI gene IDs:
"GNB2: 2783
PTEN: 5728"
Figure legend: "(C) MDA-MB-468 parental cells or GNB2 KO clones were starved and treated with scramble or PAR1 activating peptide for 5 minutes, alone or in combination with vorapaxar. The cell lysates were probed with the indicated antibodies. Phospho-AKT, pan-AKT, phospho-ERK1/2 and pan-ERK1/2 bands were quantified by the use of ImageLite software: the ratio of phospho-AKT to pan-AKT and phospho-ERK1/2 to pan-ERK1/2 normalised to the control peptide-treated conditions for WT and GNB2 KO cells (first and forth lanes, respectively) is shown."
NCBI gene IDs:
"GNB2: 2783"
Figure legend: "(D) p-S6/loading control signal from western blots experiments in which a panel of six TNBC PTEN-null cell lines and HCC70 cells that acquired resistance to AZD8186 or MK2206 were treated with vehicle, vorapaxar (10 μM), GDC0941 (1 μM) or lapatinib (1 μM) alone or in the indicated combinations. The values were normalised to vehicle treatment for all cell lines. Mean of 2 independent experiments ± SD. P values calculated by two-tailed paired student t-test *P=0.0235 and **P=0.002. Cell lines used in the experiments were: MDA-MB-468, HCC70, HCC1937, HCC38, HCC1395, BT-549, HCC70 AZD8186-resistant and HCC70 MK2206-resistant."
NCBI gene IDs:
"PTEN: 5728"
Figure legend: "Data matrix showing frequent SCNVs, significantly mutated genes (bold; Benjamini-Hochberg FDR 0.2 calculated with CHASM) and their associated pathway or family mutations discovered in cases with NPC analyzed by WES, targeted deep sequencing (TS) or SNP array (SNP-a). The frequencies of the alterations are plotted on the right. The colors and shapes denoting different types of somatic events are also applied in Figure 5a. Columns, examined cases; rows, genes; hot spot, identical mutations have been registered in COSMIC (see URLs); LOH, loss of heterozygosity. The asterisk indicates that this tumor was also subjected to SNP array profiling. PIK3CA amplification in C666 cells has been previously described."
NCBI gene IDs:
"PIK3CA: 5290"
Figure legend: "(a-d) NPC cells stably expressing either negative control shRNA (Scramble) or pooled shRNAs targeting ARID1A (shARID1A) were subjected to anchorage-independent colony formation assay (a), migration assay (b), xenograft growth assay (horizontal lines, mean values) and western blot (WB) assay with the indicated antibodies (d)."
NCBI gene IDs:
"ARID1A: 8289"
Figure legend: "(e-g) NPC cells either with or without exogenously expressing ARID1A were examined by anchorage-independent colony formation assay (e)"
NCBI gene IDs:
"ARID1A: 8289"
Figure legend: "(e-g) NPC cells either with or without exogenously expressing ARID1A were examined by anchorage-independent colony formation assay (e), migration assay (f)"
NCBI gene IDs:
"ARID1A: 8289"
Figure legend: "e-g) NPC cells either with or without exogenously expressing ARID1A were examined by anchorage-independent colony formation assay (e), migration assay (f) and WB assay with the indicated antibodies (g)."
NCBI gene IDs:
"ARID1A: 8289"
Figure legend: "(h,i) NPC cells either with or without exogenously expressing BAP1 were examined by anchorage-independent colony formation assay (h)"
NCBI gene IDs:
"BAP1: 8314"
Figure legend: "h,i) NPC cells either with or without exogenously expressing BAP1 were examined by anchorage-independent colony formation assay (h) and WB assay with indicated antibodies (i). β-actin was examined as a loading control. The data shown in a, b, e, f and h represent the mean ± s.d.; n = 3 for a, b, e and f; n = 4 for h. *P 0.05, **P 0.01. Student's t-test was used to calculate statistical significance in a-c, e, f and h; the blots shown in d, g and i are representative of three total blots run."
NCBI gene IDs:
"BAP1: 8314"
Figure legend: "(a) Data matrix showing alterations of genes involved in the ERBB-PI3K signaling pathway and their related targeting molecules. Considering space limitations, the numbers of targeting agents available for each protein are shown in parentheses. Drugs currently in phase 2 clinical trials are marked in blue, those in phase 3 are in purple, and FDA-approved drugs are in brown (see URLs)."
NCBI gene IDs:
"ERBB: 1956
PI3K: 5294///5293///5291///5290"
Figure legend: "(b) Kaplan-Meier survival curves of NPC subjects either with or without genetic lesions in the ERBB-PI3K signaling pathway. Log-rank test was used to calculate statistical significance."
NCBI gene IDs:
"ERBB: 1956
PI3K: 5294///5293///5291///5290"
Figure legend: "(A) The expression of AR was determined using Western blots (overexpressing AR in J82 cells and knocking down AR in UMUC3 cells)."
NCBI gene IDs:
"AR: 367"
Figure legend: "(B) Relative expression of the top 20 up-regulated circRNAs from the GEO dataset GSE92675 (BCa tumor tissues compared to para-tumor tissues) in response to AR modulation in J82 and UMUC3 cells. The # indicates an RNA with a relatively low expression (qRT-PCR cycle number > 35), thus the circRNA was excluded for further analysis."
NCBI gene IDs:
"AR: 367"
Figure legend: "(E) Real-time quantitative PCR (qRT-PCR) results show the knock down efficiency for these 4 circRNAs in J82 oe-AR (J82-AR) cells."
NCBI gene IDs:
"AR: 367"
Figure legend: "(F) Transwell invasion assays showed that knock down of hsa_circ_0084171 (circ_oo84171), but not the other circRNAs, can partly reverse oeAR-increased invasion in J82 cells. Scale bar, 100 μm."
NCBI gene IDs:
"circ_oo84171: 
hsa_circ_0084171: 
AR: 367"
Figure legend: "(G) MTT assays showed that shcirc_0084171 can partly reverse oeAR-increased cisplatin chemo-resistance (2 μg/ml) in J82 cells. To calculate the mean, the value of 0 µg/ml cisplatin groups were set as 1."
NCBI gene IDs:
"circ_0084171: 
AR: 367"
Figure legend: "(H) The qRT-PCR results showed that the overexpression (oe) efficacy for hsa_circ_0084171 (oecirc_0084171) in UMUC3-shAR cells."
NCBI gene IDs:
"circ_0084171: 
hsa_circ_0084171: 
AR: 367"
Figure legend: "(I) Transwell invasion assays showed that oecirc_0084171 can partly rescue shAR induced invasion deduction in UMUC3 cells. Scale bar, 100 μm."
NCBI gene IDs:
"circ_0084171: 
AR: 367"
Figure legend: "(J) MTT assays showed that oecirc_0084171 can partly overcome shAR effect for cisplatin chemo-resistance (2 μg/ml) in UMUC3 cells."
NCBI gene IDs:
"circ_0084171: 
AR: 367"
Figure legend: "B) The relative expression of circFNTA was elevated in multiple BCa cell lines (T24, J82, UMUC3, and 5637) compared to normal bladder epithelial cell line SVHUC as shown by qRT-PCR."
NCBI gene IDs:
"circFNTA: "
Figure legend: "C) The expression of circFNTA and GAPDH mRNA in J82 and UMUC3 cells treated with or without RNase R was detected by qRT-PCR."
NCBI gene IDs:
"circFNTA: 
GAPDH: "
Figure legend: "D) RNA Fluorescence in situ hybridization (FISH) demonstrated that circFNTA was predominantly localized to the cytoplasm of J82 and UMUC3 cells. DAPI was mainly localized to the cytoplasm. Scale bar, 20 μm."
NCBI gene IDs:
"circFNTA: "
Figure legend: "E) Two shcircFNTA plasmids using PLKO.1 vector were transfected into UMUC3 cells. The knock down efficacy was measured by qRT-PCR."
NCBI gene IDs:
"circFNTA: "
Figure legend: "G) The qRT-PCR results show oecircFNTA efficacy in J82 cells compared with PWPI vector (left panel) and oecircFNTA or oelinearFNTA in J82 cells (right panel)."
NCBI gene IDs:
"circFNTA: 
linearFNTA: "
Figure legend: "Transwell invasion assays showed that shcircFNTA can decrease UMUC3 cell invasion (H) more profoundly than oelinearFNTA as compared with the oevector group. Scale bar, 100 μm."
NCBI gene IDs:
"circFNTA: "
Figure legend: "Transwell invasion assays showed that shcircFNTA can increase J82 cells invasion (I) more profoundly than oelinearFNTA as compared with the oevector group. Scale bar, 100 μm."
NCBI gene IDs:
"circFNTA: 
linearFNTA: "
Figure legend: "J) MTT assays showed that oecircFNTA enhances J82 cells chemo-resistance to cisplatin (0, 1, 2, 5, 10 μg/ml were tested). This effect was more obvious in the oecircFNTA group as in the oelinearFNTA group (upper panel). MTT assays showed that shcircFNTA increases UMUC3 cells chemo-sensitivity to cisplatin (lower panel)."
NCBI gene IDs:
"circFNTA: 
linearFNTA: "
Figure legend: "K) FISH analyses revealed that circFNTA was significantly upregulated in BCa tissues as compared with the adjacent para-tumor tissues (N=41 patients) and representative images are shown. Scale bar, 250 μm."
NCBI gene IDs:
"circFNTA: "
Figure legend: "L) The qRT-PCR assays also demonstrated that circFNTA is significantly elevated in fresh BCa tissues compared to para-tumor tissues (N=23 patients)."
NCBI gene IDs:
"circFNTA: "
Figure legend: "(A) The protein expression of AR and FNTA (circFNTA host gene) were determined using Western blot and showed that shAR can decrease FNTA protein expression in UMUC3 cells and oeAR can increase FNTA protein expression in J82 cells."
NCBI gene IDs:
"circFNTA: 
AR: 367"
Figure legend: "(B) qRT-PCR results showed that mRNA levels of FNTA are not changed dramatically in UMUC3 cells with shAR and J82 cells with oeAR."
NCBI gene IDs:
"AR: 367
FNTA: 2339"
Figure legend: "(C) The mRNA levels of 4 RNA editing genes (ADAR, ADAR2, DHX9, and QKI) were tested with manipulated AR (UMUC3 cells in left panel and J82 cells in right panel). Results showed ADAR2 mRNA is negatively correlated with AR expression."
NCBI gene IDs:
"ADAR: 103
ADAR2: 104
AR: 367
DHX9: 1660
QKI: 9444"
Figure legend: "(D) Western blot analysis also confirmed that ADAR2 can be negatively regulated by AR at the protein level."
NCBI gene IDs:
"AR: 367"
Figure legend: "(E) Knock down efficiency of AR and ADAR2 (shADAR2#1 and shADAR#2) in UMUC3 cells, as determined by qRT-PCR."
NCBI gene IDs:
"ADAR2: 104
AR: 367"
Figure legend: "(F) shADAR2#1 and shADAR#2 could both reverse shAR-dependent circFNTA reduction in UMUC3 cells."
NCBI gene IDs:
"circFNTA: 
ADAR2: 104
AR: 367"
Figure legend: "(G) Transwell invasion assays confirmed that both shADAR2 constructs can partly reverse shAR-dependent UMUC3 cells invasion reduction. Scale bar, 100 μm."
NCBI gene IDs:
"ADAR2: 104
AR: 367"
Figure legend: "(H) MTT assays confirmed that both shADAR2 constructs can partly overcome shAR-dependent effects on cisplatin chemo-resistance (2 μg/ml) in UMUC3 cells."
NCBI gene IDs:
"ADAR2: 104
AR: 367"
Figure legend: "(J) ChIP assays confirmed that AR can directly bind to ADAR2 AREI/II (-572nt to -555nt)."
NCBI gene IDs:
"ADAR2: 104"
Figure legend: "(M) Co-transfection of ARE Wild type (WT) or Mutant (Mut) ADAR2 promoter pGL3-Luciferase constructs into UMUC3 cells with/without shAR (left panel), and J82 cells with/without oeAR (right panel). The luciferase assay was used to detect promoter activity."
NCBI gene IDs:
"Luciferase: 
ADAR2: 104
AR: 367"
Figure legend: "(A) Western blot analysis showed that shcircFNTA can decrease FNTA expression in UMUC3 cells (upper panel) and oecircFNTA can increase FNTA expression, and that this was more profound than using oelinearFNTA in J82 cells (lower panel)."
NCBI gene IDs:
"circFNTA: 
linearFNTA: "
Figure legend: "(B) A RNA pull-down assay was used to test the binding of circFNTA to 11 miRNAs (predicted by online database) in UMUC3 cells. The results showed that miR-328-5p, miR-370-3p and miR-920 can be pulled-down by circFNTA."
NCBI gene IDs:
"circFNTA: 
miR-328-5p: RF00772
miR-370-3p: RF00740
miR-920: RF00986"
Figure legend: "Transwell invasion assay (D) confirmed that only oemiR-370-3p can reverse oecircFNTA induced invasion in J82 cells,"
NCBI gene IDs:
"circFNTA: 
miR-370-3p: RF00740"
Figure legend: "MTT assays (E) confirmed that oemiR-370-3p can reverse oecircFNTA induced cisplatin chemo-resistance (2 μg/ml) in J82 cells. Scale bar, 100 μm."
NCBI gene IDs:
"circFNTA: 
miR-370-3p: RF00740"
Figure legend: "Transducing the miR-370-3p inhibitor into UMUC3 cells can reverse FNTA protein reduction by shcircFNTA shown by Western blot (F)"
NCBI gene IDs:
"circFNTA: 
miR-370-3p: RF00740"
Figure legend: "Transducing the miR-370-3p inhibitor into UMUC3 cells can reverse FNTA protein reduction by shcircFNTA shown by Transwell assay (G)."
NCBI gene IDs:
"circFNTA: 
miR-370-3p: RF00740"
Figure legend: "(H) MTT assays also confirmed that transducing with a miR-370-3p inhibitor in UMUC3 cells can partly reverse cisplatin chemo-resistance (2 μg/ml) reduction by shcircFNTA."
NCBI gene IDs:
"circFNTA: 
miR-370-3p: RF00740"
Figure legend: "(J) The transfection efficacy of oecircFNTA WT and oecircFNTA Mut was tested by qRT-PCR."
NCBI gene IDs:
"circFNTA: "
Figure legend: "(K) Transfection with oecircFNTA WT could increase J82 cells invasion, while oecircFNTA Mut cannot. Scale bar, 100 μm."
NCBI gene IDs:
"circFNTA: "
Figure legend: "(L) Tramsfection with oecircFNTA WT could increase J82 cells cisplatin chemo-resistance (2 μg/ml), while oecircFNTA Mut did not have this effect."
NCBI gene IDs:
"circFNTA: "
Figure legend: "(N) Luciferase reporter activity after transfection of WT and Mut FNTA 3'UTR reporter constructs into UMUC3 cells (left panel), comparing transduced miR-370-3p inhibitor vs Ctrl and J82 cells (right panel), and comparing oemiR-370-3p vs control PLV."
NCBI gene IDs:
"FNTA: 2339
miR-370-3p: RF00740"
Figure legend: "(A) Western blots show the knock-down efficiency of shFNTA in J82 and UMUC3 cells."
NCBI gene IDs:
"FNTA: 2339"
Figure legend: "(B) Transwell assays indicated that shFNTA can partly reverse oecircFNTA-increased invasion in J82 and UMUC3 cells. Quantifications are shown on the right. Scale bar, 100 μm."
NCBI gene IDs:
"circFNTA: 
FNTA: 2339"
Figure legend: "(C) MTT assays also confirmed that shFNTA can reverse oecircFNTA-increased chemo-resistance to cisplatin (2 μg/ml) in J82 and UMUC3 cells."
NCBI gene IDs:
"circFNTA: 
FNTA: 2339"
Figure legend: "Transwell assays (D, with quantitations at the right) indicated that treatment with Tipifarnib (farnesyltransferase inhibitor) can partly reverse oecircFNTA-increased invasion in J82 and UMUC3 cells. Scale bar, 100 μm."
NCBI gene IDs:
"circFNTA: "
Figure legend: "MTT assays (E) indicated that treatment with Tipifarnib (farnesyltransferase inhibitor) can partly reverse oecircFNTA-increased invasion in J82 and UMUC3 cells. Scale bar, 100 μm."
NCBI gene IDs:
"circFNTA: "
Figure legend: "(F) Western blots showed that shcircFNTA in UMUC3 or oecircFNTA in J82 cells did not change KRAS protein level significantly."
NCBI gene IDs:
"circFNTA: "
Figure legend: "(G) Raf-1 RBD GST-pull-down assays confirmed that shcircFNTA can decease KRAS activity in UMUC3 cells (upper panel), and oecircFNTA can increase KRAS activity in J82 cells (lower panel)."
NCBI gene IDs:
"circFNTA: "
Figure legend: "(H) Western blots showed that shcircFNTA can decrease ERK1/2 and MEK1/2 phosphorylation in UMUC3 cells (left panel), and oecircFNTA can increase their phosphorylation in J82 cells (right panel)."
NCBI gene IDs:
"circFNTA: "
Figure legend: "(A) UMUC3-PLKO and UMUC3-shcircFNTA cells were used to establish a subcutaneous nude mouse xenograft model, and cisplatin (1 mg/kg) was intraperitoneally administered. Images of tumors are shown after mice were sacrificed (N= 6). (B) Compared with the vector (PLKO) group, the tumor growth rate was significantly inhibited in shcircFNTA nude mice. (C) Tumor weights also decreased in the shcircFNTA group. "
NCBI gene IDs:
"circFNTA: "
Figure legend: "(D-E) The qRT-PCR results using mouse tumor tissues revealed that circFNTA expression was significantly reduced (D), and the expression of its host gene FNTA was correspondently decreased in the shcircFNTA group as compared to the PLKO group (E)."
NCBI gene IDs:
"circFNTA: 
FNTA: 2339"